Sign in Sign up for free

Last updated: 15 August 2024 at 8:21pm EST

Julie Smith Net Worth




The estimated Net Worth of Julie Smith is at least $1.17 Million dollars as of 21 May 2024. Ms. Smith owns over 27,280 units of Exelixis Inc stock worth over $145,000 and over the last 8 years she sold EXEL stock worth over $576,154. In addition, she makes $453,780 as Independent Director at Exelixis Inc.

Ms. Smith EXEL stock SEC Form 4 insiders trading

Julie has made over 1 trades of the Exelixis Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 27,280 units of EXEL stock worth $576,154 on 21 May 2024.

The largest trade she's ever made was selling 27,280 units of Exelixis Inc stock on 21 May 2024 worth over $576,154. On average, Julie trades about 1,186 units every 0 days since 2016. As of 21 May 2024 she still owns at least 5,445 units of Exelixis Inc stock.

You can see the complete history of Ms. Smith stock trades at the bottom of the page.





Julie Smith biography

Julie Anne Smith serves as Independent Director of the Company. Julie Anne Smith has been a director since September 2016. Since August 2018, Ms. Smith has served as President and Chief Executive Officer and as a member of the board of directors of Escape Bio, Inc., a privately held biotechnology company developing precisely targeted therapies for patients with genetically defined neurodegenerative diseases. From July 2017 until June 2018, Ms. Smith served as President and Chief Executive Officer and as a member of the board of directors of Nuredis, Inc., a privately held biotechnology company developing novel therapies to treat inherited neurodegenerative diseases caused by nucleotide repeat expansions. Prior to Nuredis, she served as President and Chief Executive Officer of Raptor Pharmaceutical Corp. from January 2015 until the company’s acquisition by Horizon Pharma plc in October 2016, where she also served as Executive Vice President and Chief Operating Officer from 2012 to 2014. From 2008 to 2012, Ms. Smith served as Chief Commercial Officer of Enobia Pharmaceuticals prior to the company’s acquisition by Alexion Pharmaceuticals, Inc. Previously, Ms. Smith served as Vice President of Commercial at Jazz Pharmaceuticals from 2006 to 2008, as Vice President, Global Marketing at Genzyme General from 2001 to 2005, and helped to establish the operations and business development function for the biotech start-up, Novazyme Pharmaceuticals, from 2000 to 2001. Ms. Smith began her industry career at Bristol-Myers Squibb Company in 1996. Ms. Smith served on the board of directors of Audentes Therapeutics, Inc. a publicly held clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects, from December 2016 until its acquisition by Astellas Pharma Inc. in January 2020, and previously, Ms. Smith was a Director on the Health and Emerging Companies Sections of the BIO board.

What is the salary of Julie Smith?

As the Independent Director of Exelixis Inc, the total compensation of Julie Smith at Exelixis Inc is $453,780. There are 14 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.



How old is Julie Smith?

Julie Smith is 49, she's been the Independent Director of Exelixis Inc since 2016. There are 19 older and 2 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.

What's Julie Smith's mailing address?

Julie's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.

Insiders trading at Exelixis Inc

Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.



What does Exelixis Inc do?

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.



What does Exelixis Inc's logo look like?

Exelixis Inc logo

Complete history of Ms. Smith stock trades at Exelixis Inc and Stoke Therapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
21 May 2024 EXEL Exelixis Inc Julie Smith
Director
 Sale 27,280 $21.12 $576,154
21 May 2024
5,445 ↗


Exelixis Inc executives and stock owners

Exelixis Inc executives and other stock owners filed with the SEC include: